The Cheeky Study
Cabenuva is a long-acting injectable HIV medication given once per month via intramuscular injection. Cabenuva is a combination of two HIV medications: cabotegravir and rilpivirine. It is FDA approved for people living with HIV who are stable on a HIV treatment regimen and have an undetectable viral load.
The Cheeky Study is a research study administered by Bridge HIV in partnership with Lyon-Martin Community Health Services with the aim of increasing access to Cabenuva for Transfeminine people. The study is for Transgender Women and Transfeminine Non-Binary People who are HIV+, over the age of 18, and want to try Cabenuva.
If you are interested in joining The Cheeky Study, contact Lyon-Martin’s
Positive Care Coordinator, Bo Hwang, at (415) 213-1919 or firstname.lastname@example.org.